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Background: The complete resection of liver metastases from colorectal cancer is the major determi-
nant of longterm survival. The effectiveness of current chemotherapy regimens has made treatment
algorithms more flexible and resulted in many different options. Recently, the pathological response to
chemotherapy has emerged as another important prognostic marker. Different systems have been used
to grade the pathological response in these patients.
Methods: This study prospectively evaluates the prognostic value of the pathological response grade
(PRG) in liver metastases treated with neoadjuvant chemotherapy.
Results: Between 2002 and 2006, 50 patients were treated with a sandwich chemotherapy regimen and
underwent liver resection. Complete resection was achieved in 45 patients (90%). A strong pathological
response to chemotherapy (<10% viable tumour cells in all lesions) was seen in 17 patients (34%). It was
associated with a statistically significant longer overall survival (P = 0.019) and was also identified on
multivariate analysis as an independent predictor of survival (odds ratio = 243).
Conclusions: This pilot study demonstrates the prognostic potential of the PRG, which could be used
clinically to select patients for an aggressive multimodal adjuvant algorithm. Larger multicentre studies are
required to validate this particular grading system. The keys to longterm survival are resectability and
chemo-responsiveness.
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Introduction
At present, liver resection is the only treatment for colorectal liver
metastases (CRLM) that can achieve cure. In the most recently
published series, the 5-year survival rate after resection has
reached 60%.1–4 Progress can be attributed to improvements in
surgical techniques, perioperative care and the emergence of more
effective chemotherapy regimens.
The use of neoadjuvant chemotherapy (NAC) first came to
prominence because it allows for the downstaging of initially
unresectable disease and enables complete resection.5–10 Its role in
the management of resectable disease, however, has been less clear.
Nevertheless, an increase in the use of NAC has been reported11
and is in general probably the worldwide experience. One large
randomized trial has shown a significant benefit of NAC to
progression-free survival compared with surgery alone and the
results of other multicentre trials are awaited.12 Other retrospec-
tive series have shown a benefit of NAC in specific CRLM sub-
groups, such as in patients with five or more lesions13 or in the
setting of delayed liver resection of aggressive synchronous
metastases.14 The response to neoadjuvant treatment in synchro-
nous metastases also has prognostic value.15
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Different prognostic markers and scoring systems2,11,16,17 have
been promoted for CRLM, incorporating a combination of base-
line preoperative and intraoperative characteristics. The most
common is the ‘clinical risk score’ (CRS) developed by the Memo-
rial Sloan-Kettering Cancer Centre.18,19 A clinical response to
NAC, as measured by preoperative computed tomography (CT)
scans, has also been shown to have prognostic value in the resec-
tion of liver metastases.20,21 Recently, the pathological response of
a tumour to chemotherapy has been shown to be an important
prognostic factor in the treatment of CRLM.22–24 Different patho-
logical grading systems have been proposed,25 but the common
element has been the proportion of viable tumour cells that
remain after chemotherapy.
At the McGill University hospitals in Montreal, patients with
resectable CRLM were treated with perioperative chemotherapy
sandwiched around the liver resection(s). This algorithm was ini-
tially used to target patients with advanced metastatic disease who
would require multiple interventions to achieve disease-free
status, such as patients who needed portal vein embolization or
the use of a staged approach, and patients with a synchronous
presentation of liver metastases or concurrent resectable lung
metastases. The risk of disease progression during the extended
length of time required for complete resection of all sites was of
particular concern. Neoadjuvant chemotherapy theoretically rep-
resents the earliest systemic treatment for all macroscopic and
subclinical metastatic deposits. The aim of this study was to cor-
relate longterm clinical outcomes with the pathological response
grade (PRG) after NAC in patients with resectable CRLM who
were treated with a sandwich chemotherapy regimen.
Materials and methods
Fifty patients were assessed and treated with NAC for advanced
resectable CRLM at the McGill University Health Centre
(MUHC) and Jewish General Hospital, Montreal, from April 2002
until February 2006. Data were collected from the prospective
database for hepato-pancreatico-biliary disease and verified by a
review of medical records. The study was approved by the MUHC
Institutional Review Board (A12-M114).
The treatment algorithm for advanced CRLM at the McGill
University hospitals was as follows: after consultation with the
hepatobiliary service and discussion at the multidisciplinary
tumour board, patients with resectable liver metastases were
offered NAC. The first-line regimen for CRLM was 5-fluorouracil,
leucovorin and irinotecan (FOLFIRI). The target length of treat-
ment prior to surgery was six courses. Clinical progress was moni-
tored with triphasic liver protocol CT scans every 3 months. If
adverse events prevented the completion of all cycles despite dose
adjustments or if there was clinical evidence of disease progres-
sion, the second-line regimen, FOLFOX6 (oxaliplatin-based), was
used. In addition, if lesions disappeared after treatment with NAC,
the initially planned anatomic resection was performed based on
the lesions’ locations on the initial CT scans, without the place-
ment of any type of markers. The response rate was assessed
according to the response evaluation criteria in solid tumours
(RECIST) score.26
All liver resections were performed at the MUHC. In patients
with a synchronous metastatic presentation, the clinical practice
during this study was to perform the intestinal resection first,
followed by systemic chemotherapy and then liver resection. An
interval of 4–6 weeks was required between the last course of
chemotherapy and liver resection. At liver resection, exploratory
laparotomy and intraoperative ultrasound were performed to rule
out peritoneal spread and occult liver lesions. Parenchymal
transection was performed most commonly with the aid of a
Hydrojet® instrument (ERBE Elekromedizin GmbH, Tübingen,
Germany). Extrahepatic control of the hepatic pedicles was used
only for hilar lesions and all pedicles were divided in the paren-
chyma with vascular staplers (AutoSuture International, Inc.,
Norwalk, CT, USA). All major anatomic resections of three or
more segments were performed according to the Brisbane classi-
fication system.27 Non-anatomic, wedge resections were used as
required, especially in situations in which the preservation of liver
parenchyma was critical. In patients for whom staged resections
were planned, two of six courses of chemotherapy were given
prior to the initial resection. When required, portal vein embo-
lization was performed 3–4 weeks prior to resection. The right
portal vein was embolized in two stages, starting with the poste-
rior branch and followed by the anterior branch 2–3 weeks later.
Concurrent lung metastases were referred for assessment by a
thoracic surgeon prior to starting any therapy. If the involvement
was judged to be resectable, liver resection and perioperative che-
motherapy preceded the lung resection.
The pathological specimens were examined prospectively to
assess and quantify the histological components of the liver
metastases after treatment with NAC. The findings were indepen-
dently verified by a second gastrointestinal pathologist. All
resected lesions were scored for the percentage of histological
components, including: fibrosis; mucin; necrosis, and viable
tumour cells. Two sections were scored per centimetre diameter of
the lesion. Sections were preferentially selected in areas judged to
include the highest yield of viable tumour. The PRG system was
proposed. According to this system, a complete response was indi-
cated by the absence of any viable tumour cells in all metastatic
lesions (PRG3) or a scant presence of viable tumour cells (<10%)
in all metastatic lesions (PRG2); a weak response included >10%
viable tumour cells in at least one lesion (PRG1). The strong PRG
group included all patients with PRG3 or PRG2. For example, a
patient with a complete resection of four lesions, of which one
lesion had 25% viable tumour cell content and the remaining
three were free of viable tumour cells, was included in the PRG1
group. The presence of steatosis and steatohepatitis were graded
according to Kleiner et al.28
Postoperatively, all patients received adjuvant chemotherapy. In
the case of a complete resection, six cycles of the same neoadjuvant
regimen were given to complete 12 courses in total. In the event of
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toxicity that persisted despite dosing changes, or tumour progres-
sion, the second-line or an alternative regimen was used as per
tumour board recommendations. Postoperative surveillance con-
sisted of clinical examination and routine blood work every 3
months for 2 years, and serum CEA and CT scans of the chest,
abdomen and pelvis every 6 months. Since 2005, a CT/PET
(positron emission tomography) scan has been incorporated
into the investigations for complex metastatic, recurrent or pro-
gressive disease. All recurrences were considered for further treat-
ment with chemotherapy followed by possible resection. If
unresectable and accessible, percutaneous radiofrequency ablation
was performed. If the liver involvement was diffuse, bland angio-
embolization, chemo-embolization or radio-bead embolization
were considered. Isolated hepatic arterial chemotherapy was con-
sidered if toxicity prevented further use of systemic chemotherapy.
Statistical analysis was performed with spss Version 10.0
(SPSS, Inc., Chicago, IL, USA). The chi-squared test and Mann–
Whitney U-test were used for categorical and continuous data
analyses. The log-rank test using Kaplan–Meier estimates was
used for survival analysis. Multivariate analysis was performed
using a forward stepwise Cox regression analysis for an outcome
of overall survival. A P-value of <0.05 was considered statistically
significant.
Results
Pathological analysis of liver metastases after
neoadjuvant chemotherapy
Fifty patients completed the NAC and underwent subsequent
hepatic resection. A complete pathological response of the liver
metastasis (PRG3) was seen in six patients (12%) and scant evi-
dence (10%) of viable tumour cells (PRG2) was seen in a further
11 cases (22%). The remaining patients (66%) had >10% of viable
tumour cells in at least one lesion (PRG1) (Fig. 1). The major
non-cellular histological components of the lesions were fibrosis
and necrosis. Neither had any statistical association with survival
or recurrence (data not shown). The pathological examination of
the background non-neoplastic liver found steatosis in 33 patients
(66%) and was moderate to severe in 13 (26%). Six patients had
signs of mild steatohepatitis (more than one foci of lobular
inflammation/HPF). The presence of fatty liver disease was not
statistically associated with increased morbidity or a worse sur-
vival (data not shown).
Baseline clinical characteristics
The characteristics of the patients, primary colorectal cancer and
liver metastases at initial presentation are shown in Table 1. The
majority of cases (74%) were classified as ‘advanced’ as a result of
synchronous presentation of liver metastases in 64%, planned
staged resections in 14%, application of portal vein embolization
in 10% and concurrent resectable lung metastases in 8%. The
CRS18 was considered high (3) in 72%. The strong PRG group
was associated with a significantly higher percentage of multiple
lesions and bilobar disease. In addition, the strong PRG group
included a greater proportion of patients with a high-risk CRS
that approached statistical significance.
Neoadjuvant chemotherapy
The type and details of the neoadjuvant regimens are shown in
Table 2. The majority (60%) of patients received a multi-drug
regimen including irinotecan, after which 20% received oxalipl-
atin. The median number of courses given was eight. A clinical
Figure 1 Pathological response grade (PRG)
Table 1 Demographics and characteristics of the metastatic disease
at initial presentation by pathological response grade
Group Total Strong Weak P-value
n 50 17 33
Mean age, years 56.0 56.2 56.8 0.680
Male gender, n 34 10 24 0.629
Primary rectal cancer, n 18 5 13 0.486
Lymph node positive primary, n 36 12 24 0.873
Synchronous liver metastases, n 32 13 19 0.187
Synchronous lung metastases, n 4 3 1 0.218
Multiple liver lesions, n 37 16 21 0.020
Mean size of largest lesion, cm 3.7 3.4 3.8 0.686
Bilobar lesions, n 26 13 13 0.013
Clinical risk score 18 3, n 36 15 21 0.066
Table 2 Details of neoadjuvant chemotherapy regimen (n = 50)
Group Total Strong Weak P-value
Neoadjuvant regimen
FOLFIRI 30 12 18 0.271
FOLFOX 10 3 7
Other 10 2 8
Mean number of courses, n 8 8 8 0.875
Response rate by RECIST26 0.046
Complete response 1 1 0
Partial response 23 11 12
Stable disease 19 5 14
Progressive disease 7 0 7
Portal vein embolization, n 5 2 3 0.765
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response according to the RECIST criteria (complete response/
partial response) was seen in 48% of patients. Only one patient
had a complete radiological response after receiving a neoadju-
vant FOLFIRI regimen. There was a progression of disease (PD)
that required a change in regimen in seven patients, each of whom
had received between 14 and 35 cycles in the neoadjuvant setting.
Two of these patients were initially given FOLFOX and then
switched to FOLFIRI, whereas two were treated with the converse
regimen. The other three patients progressed after receiving 5-FU/
leucovorin; one of these subsequently received FOLFIRI and two
proceeded directly to resection. No patients with PD had a strong
PRG and there was a significant correlation of PRG and RECIST
scores (P = 0.046). Portal vein embolization was performed in five
patients (10%) during the neoadjuvant period.
Operative characteristics and
perioperative complications
A total of 43 cases were considered resectable in a single operation,
whereas seven were considered to require staged resections. In
total, 58 liver resections were performed. The operative details are
outlined in Table 3. A wedge resection was completed in three of
four patients who had a synchronous solitary lung lesion. A com-
plete resection (R0) of all metastatic involvement, including liver
and lung, was achieved in 47 patients (94%). A two-stage liver
resection was required in four patients and a three-stage resection
in one. The failure to complete the planned staged resections
reflected an insufficient remnant liver in two patients and a pro-
gression of lung disease after liver resection in one patient.
There were no perioperative mortalities within 90 days of liver
resection. Serious or life-threatening (grade 3 or 4, CTC-AE v3.0;
National Cancer Institute, Bethesda, MD, USA) complications
were seen in 10% of patients. The overall morbidity rate was 30%,
as shown in Table 3. Multiple complications occurred in 12% of
patients. All perihepatic collections were amenable to percutane-
ous drainage. Sepsis occurred in one patient secondary to pneu-
monia and was associated with a bleeding duodenal ulcer,
confusion and urinary tract infection necessitating re-admission
to the intensive care unit. A perioperative blood transfusion was
required in 12 patients (24%) and was significantly associated
with a weak PRG. There were no significant differences in the
percentages of major liver resection, successful staged resection,
complete resection or morbidity between the two PRG groups.
Adjuvant therapies
All patients in this study received adjuvant chemotherapy, except
one who developed bone metastases within 3 months of resection.
The median total number of cycles received after the first hepate-
ctomy was 12 (range three to 35 courses). The most common
adjuvant chemotherapy regimen was FOLFIRI. Two patients
received hepatic arterial chemotherapy via infusion pumps. Other
adjuvant treatments for recurrence or residual disease included
radiofrequency ablation, external beam radiation, hepatic arterial
chemotherapy, radio-bead embolization and angio-embolization
(Table 4).
Longterm outcomes
At last follow-up, we noted 16 mortalities, all of which resulted
from metastatic disease. The median time of follow-up was 29.0
months. The estimated 1-year, 3-year and 5-year overall survivals
were 86%, 70% and 61%, respectively. There have been 36 recur-
rences in patients who underwent complete resection. The median
time to recurrence was 17.7 months. After complete resection, the
estimated 1-year, 3-year and 5-year recurrence-free survival rates
were 61%, 24% and 21%, respectively. Patients with a strong PRG
(including PRG2 and PRG3) had a statistically significant longer
overall survival by log-rank analysis (P = 0.019) compared with
the weak PRG group (PRG1). (Fig. 2A) The estimated 5-year
overall survival rates were 80% and 51%, respectively, for the
strong and weak PRG groups. There was a near statistically sig-
nificant difference in recurrence-free survival (P = 0.051). The
estimated 5-year recurrence-free survivals were 42% and 10%,
respectively. (Fig. 2B)
The liver was the most common site of oncological failure,
accounting for 56% of recurrences. The lung was the second most
common site and was involved in 42% of patients with recurrent
disease. Recurrences were observed in multiple sites in 15 patients.
Six recurrences were completely resected by a wedge resection of
the liver (n = 2), resection of a retroperitoneal mass (n = 1) and
wedge excision of the lung (n = 3). One liver recurrence that was
positive on CT/PET scan had a complete clinical response to sys-
temic chemotherapy and at present shows no evidence of active
disease in follow-up.
Table 3 Operative characteristics and postoperative course (n = 50)
Group Total Strong Weak P-value
Liver resection, n 58 21 37 0.520
Major hepatectomy 38 12 26
Bisegmentectomy/wedge 20 9 11
Lung resection, n 3 2 1 0.218
Staged resection, planned 7 5 2 0.858
Completed 5 3 2
Postoperative morbidity* 15 4 11 0.474
Perihepatic collection 3 2 1
Intestinal haemorrhage 1 0 1
Acute coronary syndrome 1 0 1
0.031
Sepsis 1 0 1
Deep vein thrombosis 1 0 0
Pulmonary embolus 1 0 1
Colitis, ischaemic 1 1 1
Urinary infection 5 1 4
Surgical site infection 8 0 8
Perioperative blood transfusion 12 1 11
*Common terminology criteria of adverse events (CTCAE v3.0)
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Univariate analysis for predictors of longterm survival identi-
fied a strong PRG (PRG3 + PRG2), a complete pathological
response (PRG3), receipt of a second-line NAC regimen and a
largest lesion >5 cm in diameter as statistically significant. The
variables that did not reach significance included: gender; rectal
cancer (vs. colon cancer); lymph node positive primary; synchro-
nous metastases (vs. metachronous); bilobar involvement; mul-
tiple lesions; incomplete resection (R2); RECIST (CR/PR); CRS
3; need for perioperative transfusion, and the occurrence of a
perioperative complication. When the variables with a significant
trend were put into a multivariate model along with the continu-
ous variables of age, number of lesions and number of NAC
cycles, a lack of strong PRG, increase in number of CRLM and
advanced age were found to be independent predictors of death
(Table 5).
Discussion
This study describes a system of grading the pathological response
to chemotherapy for liver metastases of colorectal cancer. A strong
PRG is indicated by the presence of <10% of viable tumour cells in
all resected lesions and represents a vigorous response to the NAC.
Patients with a strong PRG, demonstrated in 34% of this cohort,
had a significantly better survival and approached a significantly
longer recurrence-free survival. In addition, a strong PRG was also
found to be an independent predictor of survival, with an odds
ratio of 243. The other independent variables included advanced
age and number of liver lesions, both of which have been previ-
ously identified in prognostic scoring systems. The overall 5-year
survival rate of 61% observed in the entire study population is
comparable with rates reported in recently published series for
liver resection.1–4
The prognostic value of a pathological response to chemo-
therapy has been previously established in treatment of carcino-
mas of the breast,29 oesophagus30 and rectum.31,32 Two reports have
also introduced different grading systems in CRLM. Rubbia-
Brandt et al. presented the tumour regression grade (TRG), which
is based on the amount of fibrosis and residual cancer cells, in a
series of 112 patients. The major response group comprised
tumours with rare or an absence of cancer cells and was associated
Table 4 Outcomes after neoadjuvant chemotherapy and liver resec-
tion (n = 50)
Overall Strong Weak P-value
Outcomes
Recurrence, n 36 9 27 0.031
Death, n 16 2 14 0.029
Site of recurrent disease
Liver 20 4 16
Lung 15 5 10
Peritoneal/pelvic/
retroperitoneal
10 2 8
Skin/abdominal wall 3 1 2
Bone 5 0 5
Brain 3 0 3
Adjuvant chemotherapy
FOLFIRI 24 10 14
FOLFOX 15 5 10
5FU/capecitabine 12 4 8
Other 5 2 3
Received multiple
regimens, n
23 12 11
Total number of cycles,
mean
12 13 12
Adjuvant therapies
Radiofrequency ablation 3 2 1
Hepatic arterial
embolization
4 2 2
Hepatic artery pump 2 1 1
Radio-bead embolization 3 1 2
External beam radiation 1 0 1
Complete resection of
recurrence
6 1 5
0
0.0
PRG
Strong
Weak
17
33
17
26
16
16
7
10
PRG
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15
30
12
17
6
4
6
3
0.2
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Figure 2 Estimated (A) overall and (B) recurrence-free survival rates
in patients with strong and weak pathological responses (PRG)
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a higher 3-year disease-free survival.23 Furthermore, the absence
of a histological response was associated with a worse overall
survival at 5 years. By comparison, the stratification PRG groups
presented here are defined by one criterion, the percentage of
viable tumour cells, although the strong PRG group would be
closely analogous to the TRG major response group. Our analyses
did not find any correlation of outcomes with percentages of
mucin, fibrosis or necrosis, although the cohort size may have
been too small to detect such differences. Practically, the use of a
single component in the grading scale should be more widely and
easily applicable to clinical practice.
A second study of 305 patients reported by Blazer et al. showed
that overall survival was significantly different when stratified
between complete response, a major response (1–49% residual
cancer cells) and a minor response (50%).24 A multivariate
analysis found that pathological response and margin status were
the only independent predictors of survival after NAC and liver
resection. Similarly, in our series the PRG was identified as an
independent predictor of survival, but the complete resection of
all metastatic deposits was not. No patient had a positive margin
(R1), yet several had unresected lesions (R2) after failing to com-
plete all the planned staged resections although this was probably
not significant as a result of a type II error. In comparison with the
PRG, we feel that the strong or major response subgroup is better
defined by the presence of a lower percentage of viable tumour
cells. The limit of 10% for the PRG evolved through the quanti-
fication of lesions that were previously described as showing ‘scant
evidence of tumour cells in the remnant lesion’ in our published
experience with NAC.33 Although a statistical difference may exist
between the response groups, the cut-off score of 50% viable
tumour cells, similar to a system used in oesophageal cancer, may
be less specific as a marker of a biological response to chemo-
therapy as a certain degree of tumour necrosis or fibrosis exists
in tumours even without chemotherapy.23 Further prospective
studies will require larger cohorts to accurately define and validate
the prognostic limits of a strong PRG. Other pathological find-
ings, such as the histological pattern of residual disease, may also
prove to have prognostic value34,35 and could be incorporated into
future grading systems.
A complete pathological response has received by far the most
attention and has been associated with superior overall and
disease-free survival rates.22 A complete pathological response was
seen in 4% and 9%, respectively, of these study populations.23,24
Another smaller series reported a 24% complete pathological
response to FOLFOX-4.25 In our cohort, the rate of complete
pathological response was similar, at 12%. Conceptually, the sub-
stratification of a complete response group need not be the focus
of a grading system. The system should be designed to identify a
strong response to chemotherapy, in which the complete response
belongs. The difference between a complete response (PRG3) and
tumours with scant evidence of viable cells (PRG2) may largely be
a product of the sensitivity of pathological processing and sam-
pling error. A complete pathological response cannot be consid-
ered to represent a cure22 and should not be individually stratified.
This pilot study, although much smaller than those described in
the previous two reports, is a prospective study that represents the
use of a standardized protocol for pathological tissue handling
and evaluation. Retrospective studies may be limited by a higher
variance in the amount of tumour sampling and each lesion
within a resected specimen may not have been sampled in a
consistent fashion. Furthermore, it may be difficult in retrospect
to accurately determine the sampling technique. In future studies,
it will be critical to ensure the standardization of pathological
protocols and to determine the reliability and interobserver vari-
ability of any pathological grading system. The future success and
strength of this, or other, pathological grading systems will be
integral to establishing a standard of care in the processing and
analysis of resected liver metastases.
The major shortcomings of this study relate to its small cohort
size and its use of a selected CRLM population. As stated previ-
ously, a larger series will be required to prospectively validate this
grading system in a standardized treatment algorithm for CRLM,
which should, we hope, diminish confounding factors such as the
difference in transfusion rates found in this study. Furthermore,
the exceedingly high odds ratio may be a product of the small
population size of this study and local practice in our institution,
Table 5 (A) Univariate analysis: 95% confidence intervals of mean
overall survival time (days) for those binary variables for which there
was a significant trend. (B) Independent predictors of overall sur-
vival: results of forward stepwise Cox multivariate regression analy-
sis at the last step
(A) Variable P-valuea 95% CI for mean survival
No Yes
Strong PRG 0.02 1105–1751 2038–2747
Received a second-line
neoadjuvant
chemotherapy regimen
0.02 1730–2340 418–1525
Complete pathological
response
0.14 1276–1833 1925–2892
Largest lesion >5 cm
diameter
0.15 1713–2374 769–1482
(B) Variable P-value OR 95% CI for ORb
Lower Upper
No strong PRG <0.001 243.2 11.4 5196.2
Number of lesions <0.001 2.8 1.7 4.6
Age 0.003 1.1 1.0 1.2
aP-value for the log-rank test
bThe odds ratio is the odds that a patient with the parameter will reach
the endpoint (death) before a patient without. Three variables with a
significant trend from univariate analysis (complete pathological
response was excluded) and the continuous variables age, number of
lesions, size of largest liver lesion and number of neoadjuvant cycles
were considered for the model. The odds ratio of continuous variables is
expressed per unit (i.e. per unit increase in lesion number or per year,
respectively)
95% CI, 95% confidence interval; PRG, pathological response grade;
OR, odds ratio
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in which patients with recurrent disease, who were previously
identified as chemoresponsive, were treated aggressively with
numerous successive regimens of chemotherapy and other adju-
vant therapies. A difficult aspect of conducting such a multi-
institutional study in the future will concern the standardization
of the treatment of recurrent or residual disease when patients
return to their primary hospitals. In such future studies, NAC will
have to be approved and used to treat study patients, although it
has yet to be considered a standard of care for resectable CRLM
given its potential risk for perioperative complications and
unknown benefits. Even in our institution at the time of this study,
a significant percentage of patients with resectable liver metastases
did not receive NAC. It is unclear whether any benefit observed in
this study extends to patients with uncomplicated resectable
CRLM.
Consideration must also be given to medical advancements
such as the use of biological treatments, such as bevacizumab and
cetuximab, and small molecule inhibitors, which any grading
system must adjust for. In particular, these two drugs have pushed
clinical response rates beyond those for the traditional FOLFOX
and FOLFIRI regimens used in this study. The effects of these
biologics and new therapies on the prognostic strength of the PRG
remain to be established.
Conclusions
This study presents preliminary evidence that a strong pathologi-
cal response to NAC can be found in a significant proportion of
patients with liver metastases deriving from colorectal cancer and
is an independent predictor of survival. A prospective trial with a
broader population will be required to confirm the prognostic
strength of the PRG and its impact on overall survival and on
treatment algorithms for resectable and downstaged disease. In
the future, the PRG could be used as an objective biological
measure of the effectiveness of the chemotherapy. It may allow for
the identification of patients in whom an aggressive multidisci-
plinary strategy can transform recurrent or residual cancer from a
short-term prognosis into a chronic disease.
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